Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension - Full Text View

Purpose

The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension

Condition	Intervention	Phase
Hypertension	Drug: Nebivolol Drug: Metoprolol	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open-Label, Randomized Study Evaluating the Long-Term Effects of Metoprolol Versus Nebivolol as Monotherapy or in Combination With Amlodipine or Hydrochlorothiazide for the Treatment of Patients With Hypertension

Resource links provided by NLM:

Drug Information available for: Metoprolol Metoprolol tartrate Metoprolol fumarate Metoprolol succinate Nebivolol Nebivolol Hydrochloride

U.S. FDA Resources

Further study details as provided by Mylan Bertek Pharmaceuticals:

Primary Outcome Measures:

Change in average sitting DBP taken at trough at the end of treatment compared to baseline (baseline is defined as the baseline of the feeder study). [ Time Frame: During study. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

SBP, pulse pressure and heart rate at peak and trough drug effects measured in the supine, sitting and standing positions. [ Time Frame: During study. ] [ Designated as safety issue: No ]
Adverse events, ECGs, laboratory evaluations [ Time Frame: During study. ] [ Designated as safety issue: No ]


Estimated Enrollment:	1000
Study Start Date:	August 2005
Study Completion Date:	March 2008
Estimated Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1-NEB Nebivolol	Drug: Nebivolol Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
Active Comparator: 2-MET Metoprolol	Drug: Metoprolol Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.

Detailed Description:

Approximately 50 million Americans have hypertension defined as a systolic blood pressure (SBP) greater then or equal to 140 mmHg and/or a diastolic blood pressure (DBP) greater then or equal to 90 mmHg. To control blood pressure, more than 2 agents are required in many patients. The current study is a randomized, titration-to-effect, open-label, multi center study. Patients will be randomized to either nebivolol or metoprolol. The dose of the randomized treatment can be titrated as needed to achieve blood pressure control. If necessary, additional antihypertensive agents (calcium antagonist, diuretic, etc.) can be added to achieve control. Patients will be seen every 1-3 months for approximately 18 months to assess long-term safety, tolerability and effectiveness of nebivolol versus metoprolol.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Completion of previous nebivolol study
Stage 1-2 HTN at baseline of first study

Exclusion Criteria:

Recent myocardial infarction or stroke
Contraindications to beta blocker therapy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142584

Locations


United States, West Virginia
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505

Sponsors and Collaborators

Mylan Bertek Pharmaceuticals

Investigators


Study Director:	Betty S Riggs, MD, MBA	Mylan Pharmaceuticals

More Information


Responsible Party:	Andrea Miller, Vice President-Regulatory Affairs, Mylan Inc.
ClinicalTrials.gov Identifier:	NCT00142584 History of Changes
Other Study ID Numbers:	NEB324
Study First Received:	August 31, 2005
Last Updated:	March 6, 2008
Health Authority:	United States: Food and Drug Administration

Keywords provided by Mylan Bertek Pharmaceuticals:


safety and tolerability study hypertension beta-blockers

Additional relevant MeSH terms:


Hypertension Vascular Diseases Cardiovascular Diseases Metoprolol Nebivolol Anti-Arrhythmia Agents Antihypertensive Agents Sympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs	Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Vasodilator Agents Adrenergic beta-1 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists

ClinicalTrials.gov processed this record on September 23, 2016